Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00026065 · ClinicalTrials.gov registry record · Phase 1
Hypertension: Prediction of Biofeedback Success
A Phase 1 study of Essential Hypertension, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT00026065 is a Phase 1 study of Essential Hypertension that has completed, run by National Center for Complementary and Integrative Health (NCCIH). The registered enrollment target is 60 participants, below the 796-participant average among 8 other Essential Hypertension trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00026065, a Phase 1 study of Essential Hypertension, has completed, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
Hypertension, present in more than 50 million Americans, increases the risk of cardiovascular disease and its associated complications. More persons are turning to alternative medicine to deal with their health problems. Biofeedback may reduce blood pressure and/or allow the reduction of antihypertensive medications in some patients, while having no adverse effects. Yet biofeedback therapy is time-intensive and technician-intensive. Therefore, it is critical to be able to predict which patients with essential hypertension are most likely to lower his/her blood pressure using these techniques. This research proposes to test three different means of predicting whether a hypertensive subject will or will not be successful in lowering his/her blood pressure using biofeedback. Sixty hypertensive subjects will be studied over a three-year period. The results of this study will enable those caring for hypertensive persons to recommend biofeedback in an individualized way, thereby promoting adherence.
Conditions Studied
Interventions
- BEHAVIORAL Biofeedback
Study Locations (1)
Florida
- University of Florida College of Nursing - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2000-02 |
| Est. Completion | 2006-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00026065
The ClinicalTrials.gov registry entry for NCT00026065 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 796-participant average among 8 other Essential Hypertension trials with a reported enrollment target (92% lower). The listed sponsor is National Center for Complementary and Integrative Health (NCCIH), which has 203 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Essential Hypertension appearing as the primary indexed condition, and to 1 intervention - of which Biofeedback is the first listed.
NCT00026065 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT00026065 about?
NCT00026065 is a clinical study titled "Hypertension: Prediction of Biofeedback Success". Hypertension, present in more than 50 million Americans, increases the risk of cardiovascular disease and its associated complications. More persons are turning to alternative medicine to deal with their health problems. Biofeedback may reduce blood pressure and/or allow the reduction of antihyperte...
What is the current status of trial NCT00026065?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2000-02. Estimated completion is 2006-03.
What conditions does trial NCT00026065 study?
This clinical trial studies the following conditions: Essential Hypertension.
What interventions are being tested in trial NCT00026065?
The interventions under investigation include: Biofeedback (BEHAVIORAL).
Who is sponsoring clinical trial NCT00026065?
This trial is sponsored by National Center for Complementary and Integrative Health (NCCIH), which has 203 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00026065 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Essential Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Childhood-Onset Essential Hypertension Natural History Study
RECRUITING
-
Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With Hypertension
ACTIVE NOT RECRUITING
-
Uric Acid in Essential Hypertension in Children
COMPLETED · Phase 2
-
Bioequivalency Study of Perindopril Erbumine 8 mg Tablet Under Fasted Conditions
COMPLETED · NA
-
A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension
COMPLETED · Phase 3
-
Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.